Amendments to Chinese Patents Law for the Life Sciences
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
- Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank 23-06-2021
- Navigating patent eligibility in digital healthcare 22-06-2021
- The curious case of Wuhan’s Institute of Virology and remdesivir 20-04-2021
- EPO’s new examination guidelines: what you need to know 06-04-2021
- The uncertain future of antibody claims 01-04-2021
Latest biotechnology news
English High Court finds Bayer patent obvious in win for Teva
11-10-2021
The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.
